Class information for:
Level 1: TGN1412//SAFETY PHARMACOLOGY//REPEAT DOSE TOXICITY STUDIES

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
21686 352 33.0 55%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
3280 1415 IMMUNOTOXICITY//DEVELOPMENTAL IMMUNOTOXICITY//TGN1412

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 TGN1412 Author keyword 13 61% 4% 14
2 SAFETY PHARMACOLOGY Author keyword 6 19% 8% 28
3 REPEAT DOSE TOXICITY STUDIES Author keyword 4 75% 1% 3
4 NONCLINICAL TESTING Author keyword 3 100% 1% 3
5 CYTOKINE RELEASE ASSAYS Author keyword 2 67% 1% 2
6 DCTDA Address 2 67% 1% 2
7 NON CLINICAL SAFETY Author keyword 2 50% 1% 3
8 12 MONTH Author keyword 1 100% 1% 2
9 CHRONIC TOXICITY STUDIES Author keyword 1 100% 1% 2
10 ICRRU Address 1 50% 1% 2

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 TGN1412 13 61% 4% 14 Search TGN1412 Search TGN1412
2 SAFETY PHARMACOLOGY 6 19% 8% 28 Search SAFETY+PHARMACOLOGY Search SAFETY+PHARMACOLOGY
3 REPEAT DOSE TOXICITY STUDIES 4 75% 1% 3 Search REPEAT+DOSE+TOXICITY+STUDIES Search REPEAT+DOSE+TOXICITY+STUDIES
4 NONCLINICAL TESTING 3 100% 1% 3 Search NONCLINICAL+TESTING Search NONCLINICAL+TESTING
5 CYTOKINE RELEASE ASSAYS 2 67% 1% 2 Search CYTOKINE+RELEASE+ASSAYS Search CYTOKINE+RELEASE+ASSAYS
6 NON CLINICAL SAFETY 2 50% 1% 3 Search NON+CLINICAL+SAFETY Search NON+CLINICAL+SAFETY
7 12 MONTH 1 100% 1% 2 Search 12+MONTH Search 12+MONTH
8 CHRONIC TOXICITY STUDIES 1 100% 1% 2 Search CHRONIC+TOXICITY+STUDIES Search CHRONIC+TOXICITY+STUDIES
9 IMMOBILISED ANTIBODY 1 100% 1% 2 Search IMMOBILISED+ANTIBODY Search IMMOBILISED+ANTIBODY
10 IMPLANTED TELEMETRY 1 100% 1% 2 Search IMPLANTED+TELEMETRY Search IMPLANTED+TELEMETRY

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 BIOTECHNOLOGY DERIVED PHARMACEUTICALS 12 86% 2% 6
2 MONOCLONAL ANTIBODY TGN1412 8 33% 5% 19
3 CHRONIC ANIMAL TOXICITY 6 80% 1% 4
4 NON RODENT TOXICITY 6 100% 1% 4
5 TGN1412 4 28% 3% 11
6 CD4 TRANSGENIC MICE 3 60% 1% 3
7 CD28 SUPERAGONISTS 3 35% 2% 6
8 CYTOKINE STORM 2 16% 4% 14
9 RELEASE SYNDROME 2 44% 1% 4
10 1ST IN HUMAN CLINICAL TRIALS 1 100% 1% 2

Journals

Reviews


Title Publ. year Cit. Active
references		 % act. ref.
to same field
Cytokine release assays: Current practices and future directions 2014 5 23 65%
Relevance of the 1-year dog study in assessing human health risks for registration of pesticides. An update to include pesticides registered in Japan 2014 1 6 100%
Cardiovascular pressure measurement in safety assessment studies: Technology requirements and potential errors 2014 1 5 80%
A retrospective analysis of toxicity studies in dogs and impact on the chronic reference dose for conventional pesticide chemicals 2010 10 8 100%
A 1-year toxicity study in dogs is no longer a scientifically justifiable core data requirement for the safety assessment of pesticides 2010 9 8 88%
Antibody therapeutics - the evolving patent landscape 2011 2 1 100%
The future of non-human primate use in mAb development 2010 12 18 67%
Thirty years of preclinical safety evaluation of biopharmaceuticals: did scientific progress lead to appropriate regulatory guidance? 2012 5 13 54%
Safety of biologics, lessons learnt from TGN1412 2009 20 23 39%
The enhanced pre- and postnatal study for nonhuman primates: Update and perspectives 2011 9 24 46%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ.
in class
1 DCTDA 2 67% 0.6% 2
2 ICRRU 1 50% 0.6% 2
3 CBSS 1 50% 0.3% 1
4 CORP QUAL CONTROL 1 50% 0.3% 1
5 FED HLTH PROTECT CONSUMERS VET MED BGVV 1 50% 0.3% 1
6 NONCLIN EVALUAT EXPERT COMM 1 50% 0.3% 1
7 QTEST S LLC 1 50% 0.3% 1
8 SECT PHARMACOL TOXICOL BIOTECHNOL FTBB 1 50% 0.3% 1
9 TRANSLAT SCI SAFETY 1 50% 0.3% 1
10 EXCELLENCE CARDIOVASC SAFETY MECHANIST 1 29% 0.6% 2

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000134309 DEVELOPMENTAL IMMUNOTOXICITY//JUVENILE ANIMAL STUDIES//IMMUNOTOXICITY GUIDELINES
2 0.0000118188 BIOSIMILARS//BIOSIMILAR//ANTI ERYTHROPOIETIN ANTIBODIES
3 0.0000099770 FCRN//NEONATAL FC RECEPTOR//TARGET MEDIATED DRUG DISPOSITION
4 0.0000099718 COMPUTAT TOXICOL//ALTERNAT ANIM TESTING//ALTEX-ALTERNATIVES TO ANIMAL EXPERIMENTATION
5 0.0000081597 CLINICAL TRIAL RISK//CONTINUOUS IMPROVEMENT//STRATEGIE IND
6 0.0000075808 THREE RS//SYRCLE//DIRECTIVE 86 609 EEC
7 0.0000071962 TORSADES DE POINTES//TORSADE DE POINTES//ELECT ENGN CYBERNET
8 0.0000062368 HYBRIDIZATION TECHNOLOGY//IMMUNOLIGAND ASSAY//BIOASSAY GRP
9 0.0000060371 2 3 4 DIARYL 5 OXO 1 2 4 TRIAZINE 6 YLIDENEACETATES//3 4 DIARYL 1 2 4 TRIAZOLO 5 CARBOXYLATES//ADEUOVIRUS
10 0.0000057234 DRUG LAG//OFF PHARMACEUT IND//JAPANESE CLINICAL TRIALS